Sandra Coufal Net Worth

The estimated Net Worth of Sandra I Coufal is at least $21.6 Milion dollars as of 20 December 2021. Sandra Coufal owns over 7,500 units of Tricida Inc stock worth over $10,891 and over the last 6 years he sold TCDA stock worth over $21,347,597. In addition, he makes $276,000 as Independent Director at Tricida Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Sandra Coufal TCDA stock SEC Form 4 insiders trading

Sandra has made over 36 trades of the Tricida Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 7,500 units of TCDA stock worth $64,050 on 20 December 2021.

The largest trade he's ever made was buying 463,158 units of Tricida Inc stock on 2 July 2018 worth over $8,800,002. On average, Sandra trades about 26,374 units every 30 days since 2018. As of 20 December 2021 he still owns at least 99,012 units of Tricida Inc stock.

You can see the complete history of Sandra Coufal stock trades at the bottom of the page.

Sandra Coufal biography

DR. Sandra I. Coufal M.D. serves as Independent Director of the Company. Dr. Coufal is a co-founder and has served as a comanager of Sibling Capital Ventures LLC, an affiliate of one of our principal stockholders, since 2013. Dr. Coufal was a co-founder and a co-manager of Sibling Capital, LLC from 2012 to 2016. For the past 19 years, Dr. Coufal has been the Biomedical Advisor for the Genomics Institute of the Novartis Research Foundation. Dr. Coufal served as the Head of the Division of Internal Medicine at the Torrey Pines site of Scripps Clinic from 1997 until 1999, and was a member of the board of directors of Scripps Green Hospital from 1997 until 1999. Dr. Coufal founded and served on Relypsa, Inc.’s Scientific Advisory Board since 2007 and was a co-founder of Ilypsa’s Scientific Advisory Board. Dr. Coufal has served on the boards of directors of BioAesthetics Corporation and SafetySpot Inc. since February 2016 and March 2017, respectively. Dr. Coufal served as Associate Faculty in the Division of Internal Medicine for the University of California, San Diego, unsalaried. She completed an internship and residency in Internal Medicine at the University of Texas Southwestern Medical School at Dallas. Dr. Coufal received her M.D. from the University of Texas Southwestern Medical School at Dallas and received her B.S. in Science Preprofessional Studies from the University of Notre Dame and was designated a Notre Dame Scholar.

What is the salary of Sandra Coufal?

As the Independent Director of Tricida Inc, the total compensation of Sandra Coufal at Tricida Inc is $276,000. There are 13 executives at Tricida Inc getting paid more, with Gerrit Klaerner having the highest compensation of $10,168,700.

How old is Sandra Coufal?

Sandra Coufal is 56, he's been the Independent Director of Tricida Inc since 2013. There are 8 older and 7 younger executives at Tricida Inc. The oldest executive at Tricida Inc is Robert Alpern, 69, who is the Independent Director.

Insiders trading at Tricida Inc

Over the last 6 years, insiders at Tricida Inc have traded over $198,373,537 worth of Tricida Inc stock and bought 7,174,449 units worth $105,536,837 . The most active insiders traders include David P Bonita, Advisors Llc Orbi Med Capit... oraz Healthcare Capital Partners.... On average, Tricida Inc executives and independent directors trade stock every 8 days with the average trade being worth of $22,553. The most recent stock trade was executed by Robert J Alpern on 23 November 2022, trading 131,879 units of TCDA stock currently worth $27,695.

What does Tricida Inc do?

Complete history of Sandra Coufal stock trades at Tricida Inc

Tricida Inc executives and stock owners

Tricida Inc executives and other stock owners filed with the SEC include:

• Gerrit Klaerner,
  President, Chief Executive Officer, Director
• Dawn Parsell,
  Executive Vice President - Clinical Development
• Geoffrey Parker,
  Chief Financial Officer, Executive Vice President
• Edward Hejlek,
  Senior Vice President
• Dr. Gerrit Klaerner Ph.D.,
  Founder, Pres, CEO & Exec. Director
• Dr. Dawn Parsell Ph.D.,
  Exec. VP of Clinical Devel.
• Geoffrey M. Parker,
  COO, CFO & Exec. VP
• Robert L. McKague J.D.,
  Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer
• Dr. Wilhelm Stahl,
  Exec. VP & CTO
• Klaus Veitinger,
  Independent Chairman of the Board
• David Bonita,
  Independent Director
• Kathryn Falberg,
  Independent Director
• David Hirsch,
  Independent Director
• Sandra Coufal,
  Independent Director
• Robert Alpern,
  Independent Director
• Marc Cobo,
  Senior Vice President - Finance, Chief Accounting Officer
• Robert McKague,
  Executive Vice President, General Counsel, Secretary
• Edward J. Hejlek Esq., J.D.,
  Exec. VP of Intellectual Property
• Jackie Cossmon,
  VP of Investor Relations & Communications
• Annie Yoshiyama,
  VP of Fin. & Chief Accounting Officer
• Claire Lockey,
  Chief Dev. Officer and Sr. VP
• Brian M.Sibling Capital Fun...,
  
• Brian M.Sibling Capital Fun...,
  
• Brian M.Sibling Capital Ven...,
  
• Beek Jeroen B Van,
  Chief Comm Officer and Sr VP
• Steffen Pietzke,
  VP Fin & Chief Acct Officer
• Capital Partners Ii, Llc Lo...,
  
• Advisors Llc Orbi Med Capit...,
  
• Harbor Master Investors (Ca...,
  10% owner
• Wilhelm Stahl,
  EVP, Chief Tech Officer
• Brian M.Sibling Capital Ven...,
  
• Susannah Cantrell,
  EVP, Chief Comm. Officer
• Brian M.Sibling Capital Fun...,
  
• Brian M.Sibling Capital Fun...,
  
• Annie Yoshiyama,
  Senior VP, Finance and CAO
• Healthcare Capital Partners...,